Launch One Acquisition Corp. Annual Report: A Simple Breakdown

I’m writing this guide to help you understand how Launch One Acquisition Corp. performed this year. My goal is to turn complex filing data into clear information so you can decide if this company fits your investment strategy.

1. What does this company do?

Launch One is a "SPAC," or a "blank check" company. It doesn't make products or provide services yet. It raised $230 million in an initial public offering (IPO) to buy an existing private company and take it public. The team is currently looking for a partner in the biotechnology or healthcare sector, using their experience in clinical development to guide their search.

2. What happened this year?

The company’s planned merger with Minovia fell through. On January 30, 2026, they canceled the deal, citing poor market conditions and disagreements over the company's value. Launch One is now back to square one. It remains a "shell" company with cash in the bank, actively searching for a new business partner.

3. Financial health

Because the company isn't running a business yet, it has no sales or profit. It only tracks administrative costs, which totaled about $1.2 million for the year ending December 31, 2025. These costs covered legal, accounting, and insurance fees.

As of December 31, 2025, the company held about $245.4 million in its trust account, including interest. The cash backing your investment is roughly $10.67 per share. This acts as a safety net; if the company shuts down, this is the amount you would receive per share.

4. Major risks and the "Clock"

This is the most important part for you as an investor:

• The Deadline: The company must complete a merger by July 15, 2026. If they fail, they will close and return the money to shareholders. Your capital will be tied up during this time without any growth.
• The Redemption Process: If they announce a deal, you can "redeem" your shares to get your money back instead of staying invested. Be careful: you must often deliver your shares to a transfer agent two business days before a vote. If you miss this deadline or the paperwork, you might lose your right to a refund.
• The 15% Rule: To prevent large investors from blocking deals, the company stops any single shareholder from redeeming more than 15% of the shares without permission.
• Hidden Costs: Your broker might charge a fee (often around $100) to process your redemption. For small investments, this fee could eat up much of your cash.
• The Track Record: Their past projects, like CERo Therapeutics and Psyence Biomedical, have struggled. Both trade well below their initial prices. This shows that finding a partner doesn't guarantee the stock will perform well.

5. Should you invest?

Investing in a SPAC is a bet on the leadership team finding a "hidden gem." However, insiders have a strong incentive to close any deal to keep their own shares from becoming worthless. If you want a company that is already growing and making money, this is likely not for you. View this as a cash-equivalent investment with limited upside and a risky future.

Final Thought: Before buying, ask yourself if you are comfortable with your capital being locked up until July 2026. If you are looking for immediate growth, you may want to look elsewhere, as this company is currently in a holding pattern while it searches for a new partner.